Drug Profile
Research programme: influenza virus vaccines - Vivaldi Biosciences
Alternative Names: A/H7N9 LAIV - Vivaldi Biosciences; delta-NS1 LAIV for paediatrics - Vivaldi Biosciences; Influenza A/H7N9 vaccine - Vivaldi Biosciences; Int-NS1 LAIV - Vivaldi Biosciences; VB-126Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Vivaldi Biosciences
- Developer National Institute of Allergy and Infectious Diseases; Vivaldi Biosciences
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype; Influenza virus infections
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in USA (Intranasal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(In the elderly, Prevention) in USA (Intranasal)
- 21 Jan 2014 Preclinical development is ongoing for seasonal Influenza virus infections (prevention, in the elderly) in USA